SLC5A2 and acute kidney injury: Moreover, several meta-analyses of clinical trial data have concluded that use of an SGLT2 inhibitor in T2DM reduces the risk of AKI by 30–40%, and analyses of data from ‘real world’ observational studies have indicated reductions in risk of AKI by > 40% [81, 85, 86].